MX2024001367A - Nuevas sales farmaceuticas y formas polimorficas de un inhibidor de erbb y btk. - Google Patents

Nuevas sales farmaceuticas y formas polimorficas de un inhibidor de erbb y btk.

Info

Publication number
MX2024001367A
MX2024001367A MX2024001367A MX2024001367A MX2024001367A MX 2024001367 A MX2024001367 A MX 2024001367A MX 2024001367 A MX2024001367 A MX 2024001367A MX 2024001367 A MX2024001367 A MX 2024001367A MX 2024001367 A MX2024001367 A MX 2024001367A
Authority
MX
Mexico
Prior art keywords
pharmaceutical salts
polymorphic forms
erbb
btk inhibitor
btk
Prior art date
Application number
MX2024001367A
Other languages
English (en)
Spanish (es)
Inventor
Zhenfan Yang
Xiaolin Zhang
Honchung Tsui
Qingbei Zeng
Jun - Cheng Zheng
Jianan Jiang
Qinghai Guo
Shih - Ying CHANG
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of MX2024001367A publication Critical patent/MX2024001367A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024001367A 2021-08-02 2022-07-29 Nuevas sales farmaceuticas y formas polimorficas de un inhibidor de erbb y btk. MX2024001367A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021110048 2021-08-02
PCT/CN2022/109065 WO2023011358A1 (en) 2021-08-02 2022-07-29 Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor

Publications (1)

Publication Number Publication Date
MX2024001367A true MX2024001367A (es) 2024-02-27

Family

ID=85154265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001367A MX2024001367A (es) 2021-08-02 2022-07-29 Nuevas sales farmaceuticas y formas polimorficas de un inhibidor de erbb y btk.

Country Status (11)

Country Link
US (1) US20250197377A1 (https=)
EP (1) EP4380924A4 (https=)
JP (1) JP2024529533A (https=)
KR (1) KR20240042640A (https=)
CN (1) CN117794902A (https=)
AR (1) AR126673A1 (https=)
AU (1) AU2022324410A1 (https=)
CA (1) CA3224748A1 (https=)
MX (1) MX2024001367A (https=)
TW (1) TW202321223A (https=)
WO (1) WO2023011358A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4731307A1 (en) 2023-06-23 2026-04-29 Assia Chemical Industries Ltd. Solid state forms of sunvozertinib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014022790B1 (pt) * 2012-03-15 2022-04-19 Celgene Car Llc Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
CN105384694B (zh) * 2014-08-22 2020-09-04 四川海思科制药有限公司 一种取代的氨基嘧啶衍生物及其制备方法和药物用途
CN106905245B (zh) * 2015-12-23 2021-06-25 正大天晴药业集团股份有限公司 2,4-二取代的嘧啶类化合物
CN106083736A (zh) * 2016-06-21 2016-11-09 郑州泰基鸿诺医药股份有限公司 一种嘧啶类化合物、egfr抑制剂及其应用
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲(江蘇)醫藥股份有限公司 Erbb/btk抑制劑
WO2019177375A1 (ko) * 2018-03-13 2019-09-19 포로노이바이오 주식회사 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
WO2023011358A1 (en) 2023-02-09
US20250197377A1 (en) 2025-06-19
CN117794902A (zh) 2024-03-29
KR20240042640A (ko) 2024-04-02
EP4380924A4 (en) 2025-10-01
JP2024529533A (ja) 2024-08-06
CA3224748A1 (en) 2023-02-09
TW202321223A (zh) 2023-06-01
AR126673A1 (es) 2023-11-01
EP4380924A1 (en) 2024-06-12
AU2022324410A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
CY1123661T1 (el) Κρυσταλλικη μορφη ενος αναστολεα της mdm2
CO2022016323A2 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
CY1124359T1 (el) Ενωσεις και συνθεσεις για ρυθμιση δραστικοτητων κινασης μεταλλακτικου egfr
ECSP22091485A (es) Imidazolpiridazinas como moduladores de il-17
MX2022007369A (es) Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
MX2023011933A (es) Moduladores del linfoma de linaje b de casitas de ligasa e3 b (cbl-b) y usos de estos.
CL2024002623A1 (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2.
CR20190124A (es) Inhibidores de ssao de aminopirimidina
CL2011001356A1 (es) Formas cristalinas a1, h1, nf3 y nf6 de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il)-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo; proceso de preparacion; composicion y combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento o profilaxis de cancer, tumores, sarcoma, entre otros.
MX2020007947A (es) Inhibidores de erbb/btk.
PE20152032A1 (es) Compuestos de 3,4-dihidroisoquinolin-2(1h)-il
PE20181015A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MX2024009943A (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
MX2022013650A (es) Imidazopirimidinas como moduladores de il-17.
CO2021005141A2 (es) Formas cristalinas sólidas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropano-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-trihidroxi-6-(metiltio)tetrahidro-2h-pirano-2-il)bencil)fenil)butanamida y métodos para su síntesis
CO2024009144A2 (es) Inhibidores de cinasa met
DOP2024000085A (es) Compuestos dirigidos a pmp22 para el tratamiento de la enfermedad de charcot-marie-tooth
PY1886949A (es) Inhibidor del receptor del factor de crecimiento epidérmico
MX2019012967A (es) Cristal de base libre de derivados benzofurano y metodo de preparacion.
MX2024001367A (es) Nuevas sales farmaceuticas y formas polimorficas de un inhibidor de erbb y btk.
MX2021014842A (es) Sales cristalinas no higroscopicas de un compuesto de pirazol y composiciones farmaceuticas y uso de las mismas.
CO2024012427A2 (es) Pirimidinas para degradar la tirosina quinasa de bruton